Retrophin, Inc. News
Retrophin Tanks After Neurological Treatment Fails Late-Stage Study
The treatment, fosmetpantotenate, fails to meet its primary endpoint when compared to a control group being treated with a placebo, the company says.
Martin Shkreli Was Just Convicted on 3 Counts of Securities Fraud
"Pharma bro" Martin Shkreli was found guilty on three of eight counts of securities fraud.
"There is no longer any cash at the fund level" Shkreli wrote to his investors.
Sarah Hassan, daughter of pharmaceutical executive Fred Hassan, was ignored by Shkreli for nearly a year before she received returns on her original investment.
Could an exhaustive juror search be part of the Pharma Bro's master plan?
More than 250 jurors have been interviewed, but there's still no luck in assembling a jury for the so-called 'Pharma Bro.'
The jury selection process for Shkreli's trial got underway Monday and is expected to continue Tues.
One juror said Shkreli is 'the face of corporate greed in America.'
Health care stocks bound for declines after 2016 election
Stocks in the health care sector are vulnerable to declines following the 2016 presidential election, according to S&P analyst Scott Kessler.
Retrophin Announces Positive Results for Kidney Disease Drug
Shares of Retrophin surged Wednesday after announcing positive results for its drug that treats a rare kidney disease.
Retrophin (RTRX) Stock Price Target Upped at Leerink on Kidney Drug Trial
Leerink raised its price target on Retrophin's (RTRX) stock Wednesday after the company's sparsentan drug that treats a rare kidney disease saw positive results in a phase II clinical trial.
Southwest Has a Problem its Passengers Need to Know About
Southwest employees are reportedly not happy about changes in the company's work culture.
Elon Musk Was Against Covid Restrictions Until He Needed Them
Well-known for his dislike of covid mandates, Elon Musk did not shy away from using the pandemic to reschedule his testimony.